Multiple subgroup analyses of the same data increase the risk of generating false positive findings. All outcomes and planned subgroup analyses should thus be prespecified and described in the original trial registry. When outcome changes during an ongoing trial seem justifiable, publications must disclose and explain such changes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395332 | PMC |
http://dx.doi.org/10.1186/s12871-020-01105-8 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!